Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal
- Pfizer Inc is reportedly in advanced talks to buy Global Blood Therapeutics Inc for about $5 billion, bolster its portfolio and pipeline.
- Global Blood Therapeutics markets sickle-cell disease treatment, Oxbryta, which generated $194.7 million in revenue in 2021.
- Wall Street Journal says that Pfizer aims to seal a deal for GBT in the coming days, citing people familiar with the matter.
- Some people said the situation is still fluid, and other suitors are still in the mix.
- GBT announces its second-quarter results Monday.
- Bloomberg reported earlier this week that some large pharmaceutical companies are looking into a potential deal. Global Blood Therapeutics is reportedly working with advisors to evaluate potential takeover offers.
- At its current share price of $52.58, GBT has an enterprise value of $3.2 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.